SCHEMBL1286194

SCHEMBL1286194

Cc1nc2cc(Nc3cc(Cl)ncn3)cc(C)c2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.44
▸ MKNK1 Q9BUB5 1/20 0.38
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ EGFR P00533 5/20 0.34
▸ ERBB3 P21860 1/20 0.34
▸ LCK P06239 1/20 0.33
▸ DOT1L Q8TEK3 1/20 0.33
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ FGFR1 P11362 1/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ TYK2 P29597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1709139 0.84 CYP1A2 (0.35) NPC1CYP1A2CYP3A4CYP2D6MAPK1
SCHEMBL1285552 0.76 NPC1 (0.44) NPC1MKNK1CYP1A2CYP3A4CYP2D6
SCHEMBL1285874 0.74 NPC1 (0.53) NPC1MKNK1CYP1A2CYP3A4CYP2D6
SCHEMBL1285331 0.74 NPC1 (0.44) NPC1MKNK1CYP1A2CYP3A4CYP2D6
SCHEMBL1285052 0.74 NPC1 (0.55) NPC1MKNK1CYP1A2CYP3A4CYP2D6
SCHEMBL1285338 0.73 SYK (0.48) NPC1MKNK1CYP1A2CYP3A4CYP2D6
SCHEMBL13544179 0.68 ALDH1A1 (0.47) CYP1A2ALDH1A1HPGD
SCHEMBL28805101 0.67 NPC1 (0.69) NPC1MKNK1CYP1A2CYP3A4CYP2D6
SCHEMBL14323255 0.66 NPC1 (0.50) NPC1MKNK1EGFRERBB3KMT2A
SCHEMBL15492297 0.66 NPC1 (0.54) NPC1MKNK1CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 — — EP disclosed
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 — — EP disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 — — US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 — — US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 — — US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 — — US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 — — US disclosed
EP-2379529-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-26 — — EP disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088755-A1 Novel Compounds SLC26A4, F12, SLCO1B3 NPC1 1283/4885MKNK1 4735/4885CYP1A2 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback